Plain-English translation of NCT06481826 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a medication called for patients with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to at least two previous treatment plans. is a newer type of treatment designed to help the body's immune system fight cancer cells. The study wants to see if this medication is safe and effective for Chinese patients whose cancer has proven difficult to treat.
Many patients with this aggressive blood cancer run out of treatment options after their cancer stops responding to standard therapies. Researchers are testing this medication to give patients with hard-to-treat cancer a new hope and potentially effective option.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the new medication as your treatment for your cancer. The study will monitor you closely to track how well the medication works and watch for any side effects. You would attend regular visits where doctors check your health, run tests, and measure any changes in your cancer.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Enrollment target
~20 participants
Started
January 2024
Primary completion
December 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jing Ruan
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.